ClinicalTrials.gg
RecruitingNCT04306458ROBOT-2Updated May 17, 2022

RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).

An interventional study of Minimally invasive esophagectomy and daVinci Xi system in Esophageal Adenocarcinoma, sponsored by University Medical Center Mainz. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-05-17.

Sponsored by University Medical Center Mainz · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2023, 3 years 6 months ago, but the record still lists the study as recruiting.
  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Adenocarcinoma Of Esophagus with a site in Germany — 7 open to participants now, 15 under way, 5 of them phase 3. Adenocarcinoma Of Esophagus · Germany.

Planned enrollment
14th of 26
218 · median 230
Started
2021
with 1 other
No phase
3 of 29
1 open now
Primary completion
2023-05
later than 0 of 14 live
Registered
13th of 29
by date

Among the 29 studies in Adenocarcinoma Of Esophagus with a site in Germany, this one is the 14th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2021, is one of 3 with no phase, reaches primary completion later than 0 of the 14 other live ones, and was the 13th registered.

Adenocarcinoma Of Esophagus

353 studies on the registry are indexed under Adenocarcinoma Of Esophagus; 80 are open to participants now.

Browse Adenocarcinoma Of Esophagus studies →

Open to participants now

7 of the 29 studies in Adenocarcinoma Of Esophagus with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 70 Adenocarcinoma Of Esophagus studies recruiting now, 60 (86%) set no upper age limit and 2 (3%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Adenocarcinoma Of Esophagus with a site in Germany, or all of them as a file.
02

Study summary

BACKGROUND: For patients with esophageal cancer, radical esophagectomy with 2-field lymphadenectomy is the cornerstone of the multimodality treatment with curative intent. Both, conventional minimally invasive esophagectomy (MIE) and robot assisted minimally invasive esophagectomy (RAMIE) were shown to be superior compared to open transthoracic esophagectomy considering postoperative complications. However, no randomized comparison was made until now to compare MIE to RAMIE

OBJECTIVES: The objective is to evaluate the extent of lymph node dissection, efficacy, risks, quality of life and cost-effectiveness of RAMIE as an alternative to MIE as treatment for esophageal adenocarcinoma or adenocarcinoma of the gastroesophageal junction..

METHODS: This is an investigator-initiated and investigator-driven multicenter randomized controlled parallel-group, superiority trial. All adult patients (age ≥18 and ≤ 90 years) with histologically proven, surgically resectable (cT1-4a, N0-3, M0) adenocarcinoma of the intrathoracic esophagus or adenocarcinoma of the gastroesophageal junction with European Clinical Oncology Group performance status 0, 1 or 2 will be assessed for eligibility and included after obtaining informed consent. Patients (n=218) are randomized at the outpatient department to either RAMIE (n=109) or MIE (n=109). The primary outcome of this study is the total number of resected lymph nodes according to the TIGER classification for esophageal cancer lymphadenectomy.

CONCLUSION: This is the first randomized controlled trial designed to compare RAMIE to MIE as surgical treatment for resectable adenocarcinoma of the intrathoracic esophagus or adenocarcinoma of the gastroesophageal junction in the Western World. If our hypothesis is proven correct, RAMIE will result in a better lymph node dissection compared to conventional MIE. The study started in September 2019. Follow up will be 5 years. Short term results will be analyzed and published after discharge of the last randomized patient.

Read the detailed description

Aim of the study This is a randomized controlled parallel-group, superiority trial comparing RAMIE to MIE with intrathoracic anastomosis (Ivor-Lewis) in patients with resectable esophageal adenocarcinoma or adenocarcinoma of the gastroesophageal junction in the Western World.

Methods Objectives Patients with resectable esophageal adenocarcinoma or adenocarcinoma of the gastroesophageal junction are randomized at the outpatient department to either (a) robot-assisted minimally invasive esophagectomy (RAMIE) or (b) conventional minimally invasive esophagectomy (MIE). The objective is to evaluate the extent of lymph node dissection, efficacy, risks, survival and cost-effectiveness of RAMIE as an alternative to MIE as treatment for esophageal adenocarcinoma or adenocarcinoma of the gastroesophageal junction. We hypothesize that RAMIE leads to an improved lymph node dissection compared to MIE.

Study design This is a multicenter investigator-initiated and investigator-driven randomized controlled parallel-group, superiority trial comparing RAMIE to MIE. This study is conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice Guidelines. The independent ethics committee of the University Medical Center of the Johannes Gutenberg University, Mainz, Germany has approved the study. Written informed consent will be obtained from all participating patients. All centers participating in the ROBOT-2 trial have extensive experience in minimally invasive esophageal surgery and have an experience with at least 50 MIE an 50 RAMIE procedures performed.

Clinical trial monitoring will be conducted by an independent data monitor from the Johannes Gutenberg University, Mainz, Germany. A Data safety monitoring board (DSMB) will evaluate safety for patients included within this trial. All outcomes will be evaluated by a (blinded) external independent data committee board for the Upper GI International Robotic association (UGIRA).

Study protocol Patients are informed about the trial by one of our surgeons at the outpatient department. After receiving the information, all patients get one week time to consider their consent. After obtaining informed consent, randomization, with concealment of allocation, is done centrally by an online randomization program. There is no blinding for the patient, surgeon and coordinating researcher because this is difficult in daily practice. However the UGIRA committee and DSMB are blinded to the allocated intervention. This study is funded by Intuitive surgical Inc., Sunnyvale, CA, USA. Neoadjuvant (radio)chemotherapy will be administered according to current international policy. Multiple esophageal cancer biopsies for pathological analysis will be obtained through esophagogastroscopy of which 4 biopsies will be snap frozen and stored for translational research. All resection specimens will be preserved and stored (biobank) for translational research. The study will start on April 1st 2020. Inclusion will take approximately 2 years. Follow up for each patient will be 5 years. Total duration of the study will be 7 years.

Surgery All procedures (RAMIE or MIE) will be carried out by experienced surgeons with experience of at least 50 MIE and 50 RAMIE procedures. All patients will receive an epidural catheter to provide adequate postoperative analgesia. Patients will be intubated with a left-sided double-lumen tube to enable selective desufflation of the right lung during the thoracic phase in both procedures.

Antibiotic prophylaxis (Ampicillin 2000 mg and Sulbactam 1000mg) will be administered 30 minutes prior to incision. A thoracic drain will be positioned in the right hemithorax at the end of the procedure. Extubating will take place in the operating theater directly postoperatively and hereafter all patients will be admitted to the intensive care unit (ICU) for hemodynamic and respiratory monitoring. Hemodynamical and respiratory stable patients were discharged towards the surgical ward. All patients were placed on a nil-by-mouth routine for the first 3 days postoperatively. In absence of clinical signs of anastomotic insufficiency, patients started with sips of water and the oral intake was gradually increased to solid food. There was no enhanced recovery program.

Surgical procedure: RAMIE The RAMIE technique using the 4 arm daVinci Xi system was described previously (daVinci Xi system, Intuitive Surgical Inc., Sunnyvale, CA, USA).20 For the abdominal phase, the patient is placed in supine position. Robotic trocars positions are shown in figure 2a. The lesser omentum is opened and transected closely to the liver, until the left crus of the diaphragm is reached. Hereafter, the greater gastric curvature is dissected. An abdominal lymphadenectomy is performed including lymph nodes surrounding the hepatoduodenal ligament, the celiac trunk, along the left gastric and splenic artery and the lesser omental lymph nodes. The left gastric artery and vein are ligated with robotic Hem-o-lok and transected at their origin. The gastric conduit is created at the level of the crow's foot using a (robotic) endostapler .

For the thoracic phase, the patient is positioned in the left lateral decubitus position, tilted 45° towards the prone position (semi-prone). Trocars positions are shown in figure 3a. The robotic system is brought into the field at the dorsocranial side of the patient. After incision and installation of the operation robot and selective desufflation of the right lung, the pulmonary ligament is divided. Hereafter, the parietal pleura is dissected at the anterior side of the esophagus from the diaphragm up to the azygos arch. The azygos vein is ligated with robotic Hem-o-lok and divided. Dissection of the parietal pleura is continued above the azygos arch to establish dissection of the right paratracheal lymph nodes. At the posterior side of the esophagus, the parietal pleura is dissected cranially to caudally along the azygos vein, including the thoracic duct. The thoracic duct is clipped with robotic Hem-o-lok to prevent chylous leakage. The esophagus is resected en bloc with the surrounding mediastinal lymph nodes. The gastric conduit is pulled up and the specimen is removed through a small incision (mini-thoracotomy) at the location of the trocar in the 6th intercostal space. Continuity is created with a circular stapled esophago-gastrostomy, which is routinely oversewn with a V-Lock (Medtronic). An omental wrap around the anastomosis is created in all patients.

Surgical procedure: MIE For the abdominal phase, the patient is placed in supine French position. The lesser omentum is opened and transected closely to the liver, until the left crus of the diaphragm is reached. Hereafter, the greater gastric curvature is dissected. An abdominal lymphadenectomy is performed including lymph nodes surrounding the hepatoduodenal ligament, the celiac trunk, along the left gastric and splenic artery and the lesser omental lymph nodes. The left gastric artery and vein are ligated with clips and transected at their origin. The gastric conduit is created at the level of the crow's foot using an endostapler For the thoracic phase, the patient is positioned in the left lateral decubitus position, tilted 45° towards the prone position (semi-prone). After selective desufflation of the right lung, the pulmonary ligament is divided. Hereafter, the parietal pleura is dissected at the anterior side of the esophagus from the diaphragm up to the azygos arch. The azygos vein is ligated with an Endostapler or clips. Dissection of the parietal pleura is continued above the azygos arch to establish dissection of the right paratracheal lymph nodes. At the posterior side of the esophagus, the parietal pleura is dissected cranially to caudally along the azygos vein, including the thoracic duct. The thoracic duct is clipped with a clips to prevent chylous leakage. The esophagus is resected en bloc with the surrounding mediastinal lymph nodes.

The gastric conduit is pulled up and the resection specimen is removed through a small incision (mini-thoracotomy) at the location of the trocar in the 6th intercostal space. Continuity is created using stapled esophago-gastrostomy, which is routinely oversewn with a V-Lock (Medtronic). An omental wrap around the anastomosis is created in all patients.

Statistical analysis All prospective data will be statistically analyzed by the use of the statistical software SPSS. All analyses were performed according to the intention-to-treat (ITT) principle. Results are presented as risk ratios with corresponding 95% confidence intervals (CI). To evaluate significance of differences between groups, the chi-squared test was used as appropriate for categorical variables and the student's T-test and non-parametric Mann-Whitney U-test for continuous variables.

Differences over time in quality of life and pain scores between and within treatment groups were assessed using linear mixed-effects models adjusted for the baseline value. Overall and progression-free survival curves were estimated with the Kaplan-Meier method and compared with the log-rank test. All reported P-values were two-sided. Significance level was set at 0.05.

The cost-effectiveness analysis will compare the mean costs and effects for both strategies and result in an incremental cost-effectiveness ratio. Uncertainty in the balance between costs and effects will be assessed with bootstrapping. A time horizon of 5 years will be applied, and costs and effects will be discounted according to Dutch guidelines.

If the baseline characteristics differ after randomization, i.e. there is a lack of balance in the confounding factors; this will be corrected using the multivariate analysis or by using a net benefit regression approach.

Interim-analysis There will be one interim-analysis. The stopping rule used for efficacy (i.e. better outcome for minimally invasive for the primary endpoint) is the Peto-approach, meaning a p-value \<0.001. The trial will not be stopped for futility (i.e. no difference) and there is no there is no formal stopping rule for harm.

After every 50 patients, individualized patient description charts including safety parameters will be presented to the UGIRA Data Safety Monitoring Board (DSMB). The DSMB will discuss these in a plenary, telephone or online conference with the study coordinator and principal investigator present. The trial research group will discuss in a plenary session together with the DSMB the potential harm per patient and determine whether a relationship can be drawn between the surgical procedure and the adverse events. Consensus will be reached and the Institutional ethical board will be informed.

03

Conditions studied

  • Esophageal Adenocarcinoma

Keywords

  • minimally invasive esophagectomy
  • robot assisted minimally invasive esophagectomy
  • MIE
  • RAMIE
  • lymph node dissection
  • lymphadenectomy
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven adenocarcinoma of the intrathoracic esophagus and gastroesophageal junction (including Siewert I and II)
  • Surgically resectable (T1-4a, N0-3, M0)
  • Age ≥ 18 and ≤ 90 years
  • European Clinical Oncology Group () performance status 0,1 or 2
  • Written

Exclusion criteria

Exclusion Criteria:

  • Esophageal squamous cell carcinoma
  • Carcinoma of the cervical esophagus
  • Carcinoma of the gastro-esophageal junction (GEJ) with the main part of the tumor in the gastric cardia (Siewert type III)
  • Prior thoracic surgery at the right hemithorax or thoracic trauma
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
218 participants (estimated)

Study arms

  • Experimental
    Robot assisted minimally invasive esophagectomy

    Robot assisted minimally invasive esophagectomy

    Procedure: Minimally invasive esophagectomy · Device: daVinci Xi system

  • Active comparator
    Minimally invasive esophagectomy

    Conventional minimally invasive esophagectomy

    Procedure: Minimally invasive esophagectomy

Interventions

  • ProcedureMinimally invasive esophagectomy

    Conventional minimally invasive esophagectomy

  • DevicedaVinci Xi system

    robot assisted minimally invasive esophagectomy

06

What researchers measure

Primary outcomes

  1. Total number of dissected lymph nodes

    Total number of dissected lymph nodes in the resection specimen according to the TIGER classification

    Time frame: Up to 2 weeks postoperatively

Secondary outcomes

  1. Postoperative complications

    Postoperative complications and specific complications

    Time frame: Operation date till date of discharge until 52 weeks postoperatively

  2. Length of intensive care unit (ICU) and hospital stay

    Days in the ICU and hospital

    Time frame: Operation date till date of discharge until 52 weeks postoperatively

  3. In hospital mortality (IHM)

    30, 60 and 90 day mortality

    Time frame: Hospital admission period up to 90 days postoperatively

  4. Pathology results

    Radical resection (R0 and R1)

    Time frame: Up to 2 weeks postoperatively

  5. Survival

    Overall and disease free survival (2,3 and 5 year)

    Time frame: 5 years postoperatively

  6. Operation statistics

    Operating time (thoracic, abdominal and total), blood loss, intraoperative complications

    Time frame: day of operation

  7. Postoperative pain

    Postoperative pain scores on a visual analogue scale (VAS)

    Time frame: Before operation (baseline), daily during admission in the first 14 days, postoperatively: 6 weeks, 6 months and yearly post-operatively up to 5 years

  8. Cost analysis

    Cost analysis

    Time frame: date of operation until 1 year postoperatively

  9. Surgeons fatigue

    Surgeons fatigue directly after Operation assessed by Psychomotor Vigilance tests (PVT) before and after esophagectomy

    Time frame: Day of operation

  10. Quality of life after esophagectomy

    Quality of life assessed by questionnaire European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30

    Time frame: Before operation (baseline), at discharge, postoperatively: 6 weeks, 6 months and yearly up to 5 years post-operatively

  11. Postoperative Recovery

    Dutch discharge criteria (removal of thoracic tubes, no requirement of intravenous fluid resuscitation, tolerance for solid oral intake, the ability to mobilize independently and adequate pain control with oral analgesics)

    Time frame: 14 days postoperatively

  12. Quality of life after esophagectomy

    Quality of life assessed by questionnaire European Organisation for Research and Treatment of Cancer (EORTC OES18)

    Time frame: Before operation (baseline), at discharge, postoperatively: 6 weeks, 6 months and yearly up to 5 years post-operatively

  13. Quality of life after esophagectomy

    Quality of life assessed by questionnaire Short Form (SF)-36

    Time frame: Before operation (baseline), at discharge, postoperatively: 6 weeks, 6 months and yearly up to 5 years post-operatively

  14. Quality of life after esophagectomy

    Quality of life assessed by questionnaire EuroQol (EQ)-5D

    Time frame: Before operation (baseline), at discharge, postoperatively: 6 weeks, 6 months and yearly up to 5 years post-operatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Tagkalos E, van der Sluis PC, Berlth F, Poplawski A, Hadzijusufovic E, Lang H, van Berge Henegouwen MI, Gisbertz SS, Muller-Stich BP, Ruurda JP, Schiesser M, Schneider PM, van Hillegersberg R, Grimminger PP. Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus minimally invasive esophagectomy for resectable esophageal adenocarcinoma, a randomized controlled trial (ROBOT-2 trial). BMC Cancer. 2021 Sep 26;21(1):1060. doi: 10.1186/s12885-021-08780-x. PubMed 34565343 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for May 2023, 28 months after the start.

Of 27 interventional studies with no phase under Adenocarcinoma Of Esophagus, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 70. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2019
First posted
Mar 13, 2020
StartActual
Jan 18, 2021
Primary completionEst.
May 19, 2023
CompletionEst.
Jan 19, 2028
Last update
May 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04306458
Lead sponsor
University Medical Center Mainz
Responsible party
Peter Grimminger (Principle investigator, University Medical Center Mainz) — Principal investigator
First posted
Mar 13, 2020
Start date
Jan 18, 2021
Primary completion
May 19, 2023 (estimated)
Completion
Jan 19, 2028 (estimated)
Last update
May 17, 2022

Study contacts

Pieter Christiaan van der Sluis, MD,PhD
Contact
p.c.vandersluis-2@umcutrecht.nl
+31628880709
Evangelos Tagkalos, MD
Contact
evangelos.tagkalos@unimedizin-mainz.de
+4917673865294
Peter Grimminger, MD,PhD
principal investigator · JGU Medizin Mainz, dept. AVTC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion